CXCR2 and neoplasm: Experimental studies have shown that anti-programmed cell death protein 1 (PD1) and anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA4) synergizes with anti-CXCR2 or anti-Ly6G, respectively, to delay tumour growth [30,31].